2-bromo-3-cyclohexylpropanoyl chloride | 557799-48-1

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 酰卤
• 英文名称: 2-bromo-3-cyclohexylpropanoyl chloride
• 英文别名: 2-Bromo-3-cyclohexyl-propionyl chloride；2-Bromo-3-cyclohexylpropionyl chloride
• CAS: 557799-48-1
• 化学式: C₉H₁₄BrClO
• 分子量: 253.567
• InChiKey: NJCLNPSGEAXCDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-bromo-3-cyclohexylpropanoyl chloride 在 lithium aluminium tetrahydride 、 四丁基碘化铵 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Privileged structure based ligands for melanocortin-4 receptors—Aliphatic piperazine derivatives

  摘要：

  Aliphatic carbocyclic replacement of the benzyl group of compound I yielded compounds with high affinity for the melanocortin-4 receptor (MC4R). Compounds with a cyclohexyl group showed a consistent high affinity, while different polar groups with less basicity were good replacements for the original diethyl amines. Substitution of the polar group found in these privileged structures with an aliphatic moiety produced compounds with high affinity for MC4R. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.002
• 作为产物：
  描述：

  3-环己基丙酰氯 在 N-溴代丁二酰亚胺(NBS) 、 氢溴酸 作用下， 以 二氯甲烷 为溶剂， 生成 2-bromo-3-cyclohexylpropanoyl chloride
  参考文献：
  名称：

  Privileged structure based ligands for melanocortin-4 receptors—Aliphatic piperazine derivatives

  摘要：

  Aliphatic carbocyclic replacement of the benzyl group of compound I yielded compounds with high affinity for the melanocortin-4 receptor (MC4R). Compounds with a cyclohexyl group showed a consistent high affinity, while different polar groups with less basicity were good replacements for the original diethyl amines. Substitution of the polar group found in these privileged structures with an aliphatic moiety produced compounds with high affinity for MC4R. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.002

文献信息

• Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer
  作者：Xiaoqian Xue、Yan Zhang、Chao Wang、Maofeng Zhang、Qiuping Xiang、Junjian Wang、Anhui Wang、Chenchang Li、Cheng Zhang、Lingjiao Zou、Rui Wang、Shuang Wu、Yongzhi Lu、Hongwu Chen、Ke Ding、Guohui Li、Yong Xu

  DOI：10.1016/j.ejmech.2018.04.034

  日期：2018.5

  The bromodomain and extra-terminal proteins (BET) have emerged as promising therapeutic targets for the treatment of castration-resistant prostate cancer (CRPC). We report the design, synthesis and evaluation of a new series of benzoxazinone-containing 3,5-dimethylisoxazole derivatives as selective BET inhibitors. One of the new compounds, (R)-12 (Y02234), binds to BRD4(1) with a Kd value of 110 nM

  溴结构域和末端外蛋白（BET）已成为治疗去势抵抗性前列腺癌（CRPC）的有希望的治疗靶标。我们报告设计，合成和评估的一系列新的含苯并恶嗪酮的3,5-二甲基异恶唑衍生物作为选择性BET抑制剂。一种新化合物（R）-12（Y02234）以Kd值为110 nM结合BRD4（1），并以100 nM的IC50值阻断溴结构域和乙酰赖氨酸的相互作用。它也对非BET溴结构域蛋白表现出BET选择性，并在诸如22Rv1和C4-2B的前列腺癌细胞系中显示出合理的抗增殖和集落形成抑制作用。BRD4抑制剂（R）-12还可以在前列腺癌细胞的mRNA水平上显着抑制ERG，Myc和AR目标基因PSA的表达。（R）-12处理可在22Rv1衍生的异种移植模型中显着抑制前列腺癌的肿瘤生长（TGI = 70％）。这些数据表明化合物（R）-12是用于开发用于治疗CRPC的新型疗法的有前途的先导化合物。
• Amide derivatives as therapeutic agents
  申请人：——

  公开号：US20030171411A1

  公开（公告）日：2003-09-11

  This invention relates to compounds of the general formula 1 which are activators of glucokinase (GK), and which may be useful for the management, treatment, control, or adjunct treatment of diseases or conditions, where increasing glucokinase activity is beneficial, for example diseases such as IGT, Syndrome X, type 2 diabetes, type 1 diabetes, dyslipidemia, hyperlipidemia, hypertension, and obesity.

  本发明涉及一般式1的化合物，其为葡萄糖激酶（GK）的激活剂，可用于管理、治疗、控制或辅助治疗增加葡萄糖激酶活性有益的疾病或病况，例如IGT、综合征X、2型糖尿病、1型糖尿病、脂质代谢异常、高脂血症、高血压和肥胖症。
• Enantio‐ and Diastereoselective NiH‐Catalyzed Hydroalkylation of Enamides or Enecarbamates with Racemic <i>α</i>‐Bromoamides**
  作者：Jian Chen、Lifu Wu、Yue Zhao、Shaolin Zhu

  DOI：10.1002/anie.202311094

  日期：2023.10.26

  A regio-, enantio-, and diastereoselective NiH-catalyzed hydroalkylation of enamides or enecarbamates with racemic α-bromoamides or Katritzky salts with full control of the newly formed vicinal stereocenters is reported. A wide variety of enantio- and diastereomerically enriched chiral β-aminoamides and their derivatives were directly obtained through a key sequential process of enantioselective h

  据报道，烯酰胺或烯氨基甲酸酯与外消旋α-溴酰胺或Katritzky盐进行区域选择性、对映选择性和非对映选择性NiH催化加氢烷基化，完全控制新形成的邻位立构中心。通过对映选择性氢化镍-对映收敛烷基化的关键顺序过程，直接获得了多种对映体和非对映体富集的手性β-氨基酰胺及其衍生物。
• Amide derivatives useful as glucokinase activators
  申请人：Novo Nordisk A/S

  公开号：EP2305648A1

  公开（公告）日：2011-04-06

  This invention relates to acetamide derivatives of the general formula (II) which are activators of glucokinase (GK), and which may be useful for the management, treatment, control, or adjunct treatment of diseases or conditions, where increasing glucokinase activity is beneficial, for example diseases such as IGT, Syndrome X, type 2 diabetes, type 1 diabetes, dyslipidemia, hyperlipidemia, hypertension, and obesity.

  本发明涉及通式（II）的乙酰胺衍生物，它们是葡萄糖激酶（GK）的激活剂，可用于控制、治疗、控制或辅助治疗有益于提高葡萄糖激酶活性的疾病或病症，例如 IGT、X 综合征、2 型糖尿病、1 型糖尿病、血脂异常、高脂血症、高血压和肥胖症等疾病。
• Halogenated ketenes. XXII. Solvolysis of alkylhaloketene-cyclopentadiene adducts to 2-alkyltropones
  作者：William T. Brady、J. Paul Hieble

  DOI：10.1021/ja00767a041

  日期：1972.6